Role of Anti-TREK-1 Autoantibodies in SCVF
This research is investigating a serious heart problem called short-coupled ventricular fibrillation (SCVF). This condition can cause a sudden and unexpected stop of the heart (cardiac arrest). Scientists believe that in many cases, tiny substances in the blood, known as 'autoantibodies', might be attacking a specific protein in heart cells named TREK-1. This attack could make the heart behave abnormally. The study aims to confirm if these autoantibodies are a reliable way to diagnose SCVF and predict how it might progress. Researchers will look at blood samples and study heart cells in the lab to understand exactly how TREK-1 causes heart rhythm problems. Ultimately, this work could lead to better ways to identify and help people with SCVF.
At a glance
What is this study about?
This study is looking into a rare but very serious heart condition called short-coupled ventricular fibrillation (SCVF). This condition can cause the heart to suddenly stop working properly, leading to what's known as cardiac arrest. Often, there's no clear reason why this happens, which can be very distressing for patients and their families.
Recent research suggests that a key factor might be substances in the body's immune system, called 'autoantibodies'. Normally, autoantibodies fight off germs, but sometimes they mistakenly attack the body's own cells. In this case, they might be targeting a specific protein in the heart called TREK-1. When these autoantibodies attach to TREK-1, it could make the heart's electrical system act unusually, potentially causing SCVF.
The main goal of this study is to see if these TREK-1 autoantibodies can be used as a reliable way to diagnose SCVF and also to help predict how the condition might develop over time. Researchers will collect blood samples from many patients with SCVF to check for these autoantibodies. They will also study heart cells in the lab to understand exactly how the TREK-1 protein, when affected by these autoantibodies, contributes to the heart rhythm problems. This research is really important because it could lead to new tests and better ways to understand and manage this life-threatening condition.
Key takeaways
- This study investigates a serious heart condition called short-coupled ventricular fibrillation (SCVF).
- It's looking for special substances (autoantibodies) in the blood that might be attacking a heart protein called TREK-1.
- The aim is to find better ways to diagnose SCVF and understand why it happens.
- Participation involves providing blood samples and sharing your medical history.
- This research has no direct medical benefits for participants but could help future patients.
Who may be eligible?
To be part of this study, you need to be at least 18 years old. You must also have received a diagnosis of short-coupled ventricular fibrillation (SCVF) from your doctor, based on standard medical guidelines. Importantly, you need to be willing to give your written consent, meaning you understand what the study involves and agree to take part.
If you are under 18 years old, you unfortunately can't take part in this research study. Apart from this age restriction, the main criteria are having the specific heart condition and being able to agree to participate.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Have you been diagnosed with short-coupled ventricular fibrillation (SCVF)?
- Are you willing to provide written consent to participate?
- Do you understand that this study is for research, not treatment?
What does participation involve?
The detailed steps for taking part in this study are explained in a separate 'study protocol' document. Generally, if you qualify and choose to participate, it will involve providing blood samples. These samples will be checked for the presence of the anti-TREK-1 autoantibodies (special substances in your blood). You would also be asked about your overall health and medical history related to your SCVF diagnosis.
Potential risks and benefits
Locations (1)
- Institut universitaire de cardiologie et pneumologie de QuébecVerified postcodeQuébec, Canada
Common questions
What is short-coupled ventricular fibrillation (SCVF)?
It's a serious heart condition that can cause a sudden, dangerous heart rhythm problem, sometimes leading to cardiac arrest.
What are 'autoantibodies'?
They're special substances made by your immune system that can sometimes mistakenly attack parts of your own body, like certain proteins in the heart.
What is TREK-1?
It's a specific protein found in heart cells that helps control the heart's electrical activity. Autoantibodies might be targeting this protein in SCVF.
Will taking part in this study cure my SCVF?
No, this study is for research purposes to understand the condition better, and it won't directly treat or cure your SCVF.
What will researchers do with my blood samples?
They will check your blood for specific autoantibodies (anti-TREK-1) and for certain genetic markers (DPP6) that might be linked to your condition.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.